← Back to Search

Device

Active Neuro RX Gamma device for Alzheimer's Disease

N/A
Waitlist Available
Led By Corinne Fischer, MD
Research Sponsored by Vielight Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 24 compared to 24 weeks prior to study intervention
Awards & highlights

Summary

This trial will test whether the Neuro RX Gamma device is effective in improving cognitive functioning and quality of life in patients with moderate to severe Alzheimer's Disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 24 compared to 24 weeks prior to study intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 24 compared to 24 weeks prior to study intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Alzheimer's Disease
Change in European Quality of Life Scale (EQ-5 dimensions [5D], proxy version)
Change in Neuropsychiatric Inventory Questionnaire (NPI) - including Caregiver Distress ratings
+2 more
Other outcome measures
Device related Adverse Events
Rates of device/treatment anxiety
Rates of epistaxis in aspirin/anti-coagulant users
+1 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active Neuro RX Gamma deviceActive Control1 Intervention
Neuro RX Gamma device delivers low-energy near-infrared light, through 5 diodes, to the brain transcranially and intranasally
Group II: Sham Neuro RX Gamma devicePlacebo Group1 Intervention
Sham Neuro RX Gamma device is identical in appearance and sound as the active Neuro RX Gamma device but does not emit low-energy near infrared light

Find a Location

Who is running the clinical trial?

Vielight Inc.Lead Sponsor
4 Previous Clinical Trials
411 Total Patients Enrolled
Corinne Fischer, MDPrincipal InvestigatorUnity Health Toronto
2 Previous Clinical Trials
50 Total Patients Enrolled
~37 spots leftby Sep 2025